Tafluprost ophthalmic solution is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Tafluprost, a prostaglandin analog, is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow of aqueous humor.

Instill one drop in the affected eye(s) once daily in the evening.

Tafluprost ophthalmic solution is contraindicated in patients who are hypersensitive to any component of this product.

The most frequently reported treatment-related side effect is ocular hyperemia. Rare side effects observed include eye irritation and blurred vision.

Use in pregnancy: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Tafluprost ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Use in lactation: It is not known whether Tafluprost is excreted in human milk. Caution should be exercised while giving this ophthalmic solution to a nursing mother.

• For ophthalmic use only.
• To avoid possible contamination of the drops, do not touch the dropper tip to any surface.
• Should be used with caution in patients with active intraocular inflammation (e.g., iritis/uveitis).
• If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes between applications.

Use in children: Use in pediatric patients is not recommended.

Use in elderly patients: No overall differences in safety and effectiveness have been observed between elderly and other adult patients.

Drugs for miotics and glaucoma